STUTTGART, Germany I April 15, 2013 I The emerging therapeutic class of antibody-drug conjugates (ADC) is coming of age. Two approved and marketed ADC drugs utilizing each one of the two major technologies (auristatin and maytansin derivatives) have paved the way for a total of further 33 ADCs in clinical studies and further six ADCs in IND enabling studies. Adcetris posted US sales of US$ 138 mln in its first full year (2012) after launch. With the start of marketing of Kadcyla, sales of this therapeutic class are expected to reach blockbuster size. New linker and toxic payload technologies are being developed and the first representative ADCs from the new technologies are approaching clinical proof of concept testing.
La Merie Publishing released its brand new Competitive Intelligence Report about Antibody-Drug Conjugates (ADC). The Competitor Analysis: Antibody-Drug Conjugates provides a competitor evaluation in the field of tumor targeting antibodies conjugated via a linker with a drug payload for treatment of cancer as of April 2013. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date.
Specifically, the report addresses:
- Adcetris Pipeline
- Antibody-Drug Conjugates with Auristatin Derivatives
- Antibody-Drug Conjugates with Pyrrolobenzodiazepine (PBD) Derivatives
- Kadcyla Pipeline
- Antibody-Drug Conjugates with Maytansinoid Derivatives
- Antibody-Drug Conjugates with Irinotecan Derivatives
- Antibody-Drug Conjugates with Doxorubicin
- Antibody-Drug Conjugates with Calicheamicin Derivatives
- Antibody-Drug Conjugates with Duocarmycin Derivative
- Antibody-Drug Conjugates with Various Drugs
- Antibody-Drug Conjugates with Not Disclosed Drugs
- Other Immunoconjugates
- Antibody-Drug Conjugates: R&D Collaboration Agreements
- Antibody-Drug Conjugates: Licensing Agreements About La Merie
- Corporate ADC R&D Pipelines
Source: La Merie Publishing
Post Views: 154
STUTTGART, Germany I April 15, 2013 I The emerging therapeutic class of antibody-drug conjugates (ADC) is coming of age. Two approved and marketed ADC drugs utilizing each one of the two major technologies (auristatin and maytansin derivatives) have paved the way for a total of further 33 ADCs in clinical studies and further six ADCs in IND enabling studies. Adcetris posted US sales of US$ 138 mln in its first full year (2012) after launch. With the start of marketing of Kadcyla, sales of this therapeutic class are expected to reach blockbuster size. New linker and toxic payload technologies are being developed and the first representative ADCs from the new technologies are approaching clinical proof of concept testing.
La Merie Publishing released its brand new Competitive Intelligence Report about Antibody-Drug Conjugates (ADC). The Competitor Analysis: Antibody-Drug Conjugates provides a competitor evaluation in the field of tumor targeting antibodies conjugated via a linker with a drug payload for treatment of cancer as of April 2013. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date.
Specifically, the report addresses:
- Adcetris Pipeline
- Antibody-Drug Conjugates with Auristatin Derivatives
- Antibody-Drug Conjugates with Pyrrolobenzodiazepine (PBD) Derivatives
- Kadcyla Pipeline
- Antibody-Drug Conjugates with Maytansinoid Derivatives
- Antibody-Drug Conjugates with Irinotecan Derivatives
- Antibody-Drug Conjugates with Doxorubicin
- Antibody-Drug Conjugates with Calicheamicin Derivatives
- Antibody-Drug Conjugates with Duocarmycin Derivative
- Antibody-Drug Conjugates with Various Drugs
- Antibody-Drug Conjugates with Not Disclosed Drugs
- Other Immunoconjugates
- Antibody-Drug Conjugates: R&D Collaboration Agreements
- Antibody-Drug Conjugates: Licensing Agreements About La Merie
- Corporate ADC R&D Pipelines
Source: La Merie Publishing
Post Views: 154
